EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

TGF-β1 Signaling Impairs Metformin Action on Glycemic Control

Quan Pan iD, Weiqi Ai, Shaodong Guo iD

International Journal of Molecular Sciences · 19.02.2024 · 25 (4) · 2424

DOI: 10.3390/ijms25042424 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Journal of Molecular Sciences, online erschienen am 19.02.2024. Verfasst von Quan Pan und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Nutrition, College of Agriculture and Life Sciences, Texas A&M University, College Station, TX 77843, USA. Hauptthemen laut MEDLINE: Metformin, Diabetes Mellitus, Type 2. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 53 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIDDK NIH HHS, National Institutes of Health, American Diabetes Association Career Development Award.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Hyperglycemia is a hallmark of type 2 diabetes (T2D). Metformin, the first-line drug used to treat T2D, maintains blood glucose within a normal range by suppressing hepatic glucose production (HGP). However, resistance to metformin treatment is developed in most T2D patients over time. Transforming growth factor beta 1 (TGF-β1) levels are elevated both in the liver and serum of T2D humans and mice. Here, we found that TGF-β1 treatment impairs metformin action on suppressing HGP via inhibiting AMPK phosphorylation at Threonine 172 (T172). Hepatic TGF-β1 deficiency improves metformin action on glycemic control in high fat diet (HFD)-induced obese mice. In our hepatic insulin resistant mouse model (hepatic insulin receptor substrate 1 (IRS1) and IRS2 double knockout (DKO)), metformin action on glycemic control was impaired, which is largely improved by further deletion of hepatic TGF-β1 (TKObeta1) or hepatic Foxo1 (TKOfoxo1). Moreover, blockade of TGF-β1 signaling by chemical inhibitor of TGF-β1 type I receptor LY2157299 improves to metformin sensitivity in mice. Taken together, our current study suggests that hepatic TGF-β1 signaling impairs metformin action on glycemic control, and suppression of TGF-β1 signaling could serve as part of combination therapy with metformin for T2D treatment.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

MetforminDiabetes Mellitus, Type 2HumansMiceAnimalsTransforming Growth Factor beta1Glycemic ControlGlucose

Stichwörter der Autor:innen

AMPKFoxo1LY2157299TGF-β1hepatic glucose productionmetformin

Substanzen

MetforminTransforming Growth Factor beta1Glucose

Autor:innen und Institutionen

  • Department of Nutrition, College of Agriculture and Life Sciences, Texas A&M University, College Station, TX 77843, USA.

ORCID-Profile: Quan Pan, Shaodong Guo

Förderung

  • NIDDK NIH HHS
  • National Institutes of Health
  • American Diabetes Association Career Development Award
  • Faculty Start-up funds from Texas A&M University Health Science Center and AgriLife Research
  • USDA National Institute of Food and Agriculture

Zitieren

APA

Pan, Q., Ai, W., & Guo, S. (2024). TGF-β1 Signaling Impairs Metformin Action on Glycemic Control. International Journal of Molecular Sciences, 25(4), 2424. https://doi.org/10.3390/ijms25042424

Vancouver

Pan Q, Ai W, Guo S. TGF-β1 Signaling Impairs Metformin Action on Glycemic Control. International Journal of Molecular Sciences. 2024;25(4):2424. doi:10.3390/ijms25042424

BibTeX
@article{Pan2024,
  author = {Pan, Quan and Ai, Weiqi and Guo, Shaodong},
  title = {TGF-β1 Signaling Impairs Metformin Action on Glycemic Control},
  journal = {International Journal of Molecular Sciences},
  year = {2024},
  volume = {25},
  number = {4},
  pages = {2424},
  doi = {10.3390/ijms25042424}
}
Kostenlos starten →